What is the main business of DR. Klimas Group?

The main business activity of DR. Klimas Group focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on July 20, 2023.

Where is the headquarters located?

The headquarters is located at: Osiedle Dywizjonu 303 22D, 31-873 Kraków.

Who is on the management board?

The management board consists of: Krzysztof Klimas (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 10,000 (approx. $2,701).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

The company reported a revenue of USD 49,940 in 2025.

Is the company profitable?

Yes, in 2025 the company achieved a net profit of USD 11,703.

What is the largest operating cost?

The largest operating cost category falls under external services. This category amounted to USD 18,163 in 2025, representing 49% of all operating expenses.

DR. Klimas Groupsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2023-07-20

Share capital

10,000.00 PLN

Registered address

Osiedle Dywizjonu 303 22D/U1, 31-873 Kraków, Poland

Financials

Filing timeliness

1 of 3 financial statements was filed late (for 2025, 8 days late).

202523/07/2026
202429/05/2025
202326/06/2024

Filed on timeDelayFiling deadline

The statements for 2023–2024 report only zeros (no activity).

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 49.94kMedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD 11.70kMedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 37.01kMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 29.79kMedianUSD 883.09kAverageUSD 31.39m

Industry

Authorized Representatives

Krzysztof Klimas – President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Anna Klimasage 66	10	$270.12	10%
Krzysztof Klimasage 63	70	$1,890.87	70%
Paweł Klimasage 27	10	$270.12	10%
Kinga Stósage 32	10	$270.12	10%

Krzysztof Klimas, Anna Klimas and Paweł Klimas hold a combined 90% – the ownership structure indicates family control.

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2023-08-07.

mBank
21 1140 2004 0000 3702 8394 1825

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Nov 20, 2023	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	––	Prezes Polskiej Agencji Rozwoju Przedsiębiorczości

Competitors

Name	Revenue	Website
DR Andresp. z o.o.	$453,987.42	drandre.pl
Stem Cells SpinS.A.	$287,714.76	stemcellsspin.com.pl
F1 PharmaS.A.	$272,113.66	f1pharma.pl
Ti-Comsp. z o.o.	$157,549.77	ticomglobal.com
LideoS.A.	$95,067.91	lideo.tech
Munar PharmaS.A.	$85,649.72	munar.pl
Ampliconsp. z o.o.	$48,330.99	amplicon.pl
Xenira Pharmaceuticalssp. z o.o.	$26,670.82	xenirapharma.com

Change history

Date	Event
2024-11-27	Address change (Ul. Szybka 29/6, 31-831, Kraków → Osiedle Dywizjonu 303 22d/U1, 31-873, Kraków)
2023-07-20	Entered in the register

FAQ

Last updated: 2026-09-23